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ABSTRACT  
Quality by Design (QbD) is a methodical approach to pharmaceutical product development that begins with predefined objectives and 
emphasizes product and process comprehension and process control based on sound science and quality risk management. Pharmaceutical 
development should lead to the design a quality product and its manufacturing process to meet the QTPP and CQA parameters. To arrive at the 
robust product development QbD articulation is important which is missing in most of the reviews. This review articulates the QbD elements in 
the product development. QbD process stars with identification of QTPP and source CQA from QTPP. CMAs and CPPs are derived wi th risk 
assessment from the product ingredients and process. Their impact on the CQAs can be studies with DoE tools. The information and knowledge 
gained from pharmaceutical development studies and manufacturing experience provide scientific understanding to support the design space 
and control strategy. Product process follows life cycle management approach with continuous improvement. PAT tools are utilized for the 
online monitoring of the processes. This review paper is dedicated to provide QbD element articulation in product development and its unique 
applications in the various areas of the product development such as Biotechnology, Nanotechnology products, Nasal products, Inhalation, 
Injectable products, Targeted drug delivery, complex Solid oral, Transdermal and topical products, Bioavailability and dissolution 
enhancement, Analytical processes and API manufacturing etc. Current trends in the technical application of the PAT tools are discussed.  
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Quality by Design (QbD) has supported both industry and 
FDA to achieve scientific, risk based, and proactive approach 
to pharmaceutical product development. [1] The QbD is a 
systemic approach to pharmaceutical product development 
which leads to formulations and manufacturing processes 
with desired quality attributes. [2] Pharmaceutical QbD may 
include achieving meaningful control strategy that are based 
on clinical performance to increase process capability by 
enhancing product and process design. [3] The theme of QbD 
is Quality can’t be tested into the product, but it should be 
built into it. [4]   
Studies have shown that the Lifecycle management 
approach for the product development supports 
establishment of the design space and working within design 
space is not considered as change by the regulatory agencies. 
[5] The International Council for Harmonisation of Technical 
Requirements for Pharmaceuticals for Human Use (ICH) 
guidelines ICH Q8 (Pharmaceutical Development), ICH Q9 
(Quality Risk Management) and ICH Q10 (Pharmaceutical 
Quality Systems) are basis for the QbD in product 
development to achieve the quality product. [6] Prime 
requirement for the QbD implementation are to establish 
relationship of the product CQAs with CMAs and CPPs. [7] 
QbD reduces post approval regulatory submissions with 
design space development and facilitates novel approaches 
to process validation which is continuous process 
improvement and lifecycle management. [8] 
Most of the review articles presented partial elements of 
QbD and articulation is missing for the application. This 
review article focuses on the QbD elements articulation 
along with supporting elements to achieve the quality 
products with design space. Current trends in the PAT 
applications are described along with unique application of 
QbD in product development. 
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Elements of Quality by Design (QbD) 
QbD encompasses following listed elements of 
pharmaceutical development. These elements will lead to the 
product with intended performance characteristics. 
Pharmaceutical development will provide a complete 
understanding of the product and its manufacturing process 
by application of QbD elements. [9] 
 Quality target product profile (QTPP)  
 Critical quality attributes (CQAs)  
 Critical material attributes (CMAs)  
 Critical process parameters (CPPs)  
 Control strategy 
 Product Lifecycle Management and Continual 
Improvement  
Supporting elements including  
 Risk assessment 
 Design of Experiment (DoE)  
 Process Analytical Technologies (PAT) 
These elements are described in the following sections along 
with their articulation in product development. 
Quality Target Product Profile (QTPP)  
QTPP identification is the starting point for the product 
development. The US Food and Drug Administration (FDA) 
QbD initiative provides an enhanced assessment approach 
by introducing the concept of a QTPP. [10] QTPP is defined as, 
“A prospective summary of the quality characteristics of drug 
product that ideally will be achieved to ensure the desired 
quality, taking in to account safety & efficacy of drug 
product.” QTPP is not specification because it includes tests 
such as bioequivalence or stability that are not carried out in 
batch to batch release. Based on the clinical and 
pharmacokinetic characteristics as well as the in vitro 
dissolution and physicochemical characteristics of the 
reference product QTPP can be defined for the product. [11, 12] 
QTPP parameters for example Generic Acetriptan Tablets, 20 
mg are presented in the below table 1. [13] 
 
 
Table 1: Quality Target Product Profile (QTPP) parameters 
 
Originator’s product characteristic will be strictly used for 
defining the QTPP for the Biosimilar products. [14] Sterile 
Product QTPP may be unique in terms of need for 
administration devices and requirements specific to sterile 
products such as endotoxin limits. [15] 
QTPP identification will be followed by CQAs identification 
based on the risk assessment. CQAs will be derived from the 
QTPP considering impact on the safety of the patients. 
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Critical Quality Attributes (CQAs) 
A Critical quality attribute (CQA) is “A physical, chemical, 
biological, or microbiological property or characteristic that 
should be within an appropriate limit, range, or distribution 
to ensure the desired product quality.” CMAs and CPPs are 
identified during product development and are linked to the 
CQAs. Risk assessment process will be used to facilitate this 
evaluation. CQAs include but are not limited to Assay, 
Dissolution, Sterility, Degradation products and Crystallinity 
etc. [16, 17] Active Pharmaceutical Ingredient CQAs can also be 
controlled with QbD. [18] 
Identification of the CQAs is followed by risk assessment of 
Active pharmaceutical ingredient and Formulation variables 
to arrive at the CMAs. 
Critical Material Attributes (CMAs) 
CMAs includes physical, chemical, biological, or 
microbiological properties or characteristics of an input 
material used in the product development. CMAs should be 
within an appropriate limit to ensure the desired quality of 
that drug substance, excipient or in-process material. Risk 
assessment process is used to derive the CMAs. [19, 20] 
Identification of the CMAs is followed by identification of the 
CPPs of the process used for the product manufacture with 
use of the risk assessment tools. 
Critical process parameters (CPPs)  
A process parameter is critical when a realistic change in 
that parameter can cause the product to fail to meet the 
QTPP. For example if development studies showed that the 
granulation was affected by realistic changes in impeller 
speed or granulation time then these should be identified as 
CPPs. Risk assessment process can lead to identification of 
the CPPs. Control strategies should be defined for the 
identified CPPs. CPPs are studied for their impact on the 
CQAs. Critical parameters of process and materials and their 
link with the product CQAs is presented in the following 
figure 1. [21, 22] 
 
 
Figure 1: Critical parameters of process and materials with their link to CQAs 
 
Resources can be utilized in the most critical areas with QbD 
process. Dossier with QbD compliant product development 
help FDA reviews decrease post-approval regulatory 
submissions required to make process changes. [23] Process 
modeling tools such as PAT can play a role in developing 
robust and economically efficient manufacturing processes. 
[24] 
Based on the knowledge of the CMAs and CPPs and their link 
to the CQAs robust process development will be carried out. 
Formulation development trials at lab will be scaled to the 
Pilot or Production scale and Control strategies will be 
derived. DoE can be used for the experimentation of the CPPs 
and CMAs to study their impact on the CQAs to derive the 
design space.  
Control Strategy 
Control strategy is defined as “a planned set of controls, 
derived from current product and process understanding 
that assures process performance and product quality”. Risk 
assessment is used to derive the Control strategy for the 
CQAs. The control strategy is derived for the procedural 
controls, in-process controls, lot release testing, process 
monitoring, characterization testing, comparability and 
stability testing. [25] A control strategy may include design 
spaces and final product specifications. Control strategy for 
the commercial scale will be proposed in the submission to 
FDA. [26] 
Design space is designed for the product which will be 
verified by the regulatory agency. The Design Space 
encompasses the proven acceptable ranges for CMAs, CPPs 
and CQAs. Normal operating ranges are a part of the design 
space [27]. Risk assessment, experimental design along with 
the use of literature / prior experience can be leveraged to 
derive the design space for the product. [28] Material attribute 
design space is independent of scale and configuration of 
process equipment and the related process variables. Thus 
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post-approval changes of equipment scale, nameplate, or 
location would not require any regulatory approval. [29] 
Product submission will include the proposed product 
commercialization design space with QbD Product life cycle 
and continual improvement approach. 
Product Lifecycle Management and Continual 
Improvement 
Risk assessment throughout product development leads to 
robust product with less deviations. [30] Manufacturing 
process performance will be monitored to confirm that it is 
working within design space. Process capability and trend 
analysis will be performed. Continual improvement of the 
drug product will be performed with knowledge gained from 
the product. [31] 
Supporting elements to achieve the product development 
with QbD application are Risk assessment, DoE and PAT. 
These tools are discussed in the following sections. These are 
integral part of the QbD. 
 
Risk assessment 
QRM principles are used to achieve the enhanced knowledge 
of the product. [32] Commonly used tools are Ishikawa 
diagram & Failure Mode and Effects Analysis (FMEA). [33] 
QRM helps in identifying effect of CMAs and CPPs on CQAs. 
This risk assessment helps regulators to achieve the greater 
understanding of the product and leads to patient benefits. 
[34] 
Risk assessment of the drug substance attributes performed 
to evaluate the impact that each attribute could have on the 
drug product CQAs. The outcome of the assessment and the 
accompanying justification is provided as a summary in the 
Pharmaceutical development report. The relative risk that 
each attribute presents was ranked as high, medium or low. 
The high risk attributes warranted further investigation 
whereas the low risk attributes required no further 
investigation. The medium risk is considered acceptable 
based on current knowledge. Further investigation for 
medium risk may be needed in order to reduce the risk. [35] 




Figure 2: Overview of a typical QRM process 
 
QRM process described above could help the oral Peptide 
delivery system development which has many formulation 
barriers. QRM helps to manage on the resources (human, 
financial & time) related to the final product quality in more 
productive way. [38] 
Identified CMAs and CPPs can be studied with DoE tools for 
their impact on CQAs to achieve design space. 
Design of Experiments (DoE)  
DoE process is used for the attribute interaction studies. 
Studies on CPPs and CMAs for their impact on the CQAs can 
be carried out with DoE to arrive the design space. This will 
lead to the product meeting CQAs and QTPP. [39] DoE studies 
can be carried out at lab scale or on pilot scale processes. [40] 
Legacy drug products are developed with application of 
Multivariate statistical analysis and DoE to achieve design 
space. [41] QbD, PAT, real-time data generation and control 
monitoring systems knowledge will be better captured, 
managed and shared during product life cycle for product 
continuous improvements. [42] 
Process Analytical Technology (PAT) 
PAT tool can be used for the product development from early 
development to commercialization.  FDA PAT Guidance and 
ICH Q8 suggest for the PAT tool utilization to monitor 
process online. [43, 44] PAT tools are classified as Multivariate 
Tools for Design, data acquisition and analysis, process 
analyzers, process control and continuous improvement and 
knowledge management. [45, 46]  Current trends in the PAT 
tools application are described for product development.
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NIR spectroscopy is used in coating process, [47] 
Determination of content uniformity, compression force and 
crushing strength for Orbifloxacin tablets, Film coat curing 
and release monitoring, [48, 49, 50] Monitoring blend potency 
and uniformity in the manufacturing of an oral solid dosage 
product. [51] PAT tools used for process monitoring and 
control tools that enables monitoring of real-time release. [52] 
Confocal Raman microscopy to study content uniformity and 
the polymorphic form of a drug substance distributed within 
a lipid based inhalable powder. [53] Additional application of 
NIR can include for design and scale-up of a batch mixing 
process, [54] Coating thickness monitoring for its impact on 
dissolution. [55] Thus PAT can support for QRM to arrive at 
design space. [56] 
This discussion summarizes the articulation of the QbD 
elements in the product development. QbD process stars 
with QTPP and CQA identification. CMAs and CPPs are 
derived with risk assessment from the product 
understanding. Their impact on the CQAs can be studies with 
DoE tools. This will lead to identification of the control 
strategy and design space. Product process will be follow life 
cycle management approach with continuous improvement. 
PAT tools are utilized for the online monitoring of the 
processes. All this lead to robust product development. 
Following literature reports of unique applications of QbD 




Xu X et al. prepared Superoxide dismutase containing 
liposome formulations using freeze and thaw unilamellar 
vesicles followed by use of risk analysis and D-optimal 
statistical design resulting in liposomes with 6 months 
stability in aqueous dispersion state at 4 °C. [57] 
Monoclonal Antibody Product 
Nagashima H et al. used QbD for cell culture process of 
monoclonal antibody production resulting in the 
establishment of a design space with QRM. [58] 
Peptide Product 
Reihaneh Manteghi et al. prepared antimicrobial peptide 
modification and formulation design analyzed the potential 
risks in the antimicrobial Peptide PEGylation process. [59] 
Biosimilar product 
Rathore AS et al. studied development of 
a purification process for the production of a biosimilar 
product granulocyte colony-stimulating factor (GCSF) using 
QbD. [60] 
Topical Formulations 
Marto J et al. prepared starch based Nanocapsules 
formulation of lipophilic bioactive molecule for topical drug 
delivery and studies indicated a good physical stability, 
safety and cosmeticity. [61] 
Creams 
Mendonsa NS et al. formulated topical creams of 
Hydrocortisone acetate via hot melt extrusion technology 





Nanostructured lipid carriers 
Qian Kang et al. formulated and optimized Tripterine loaded 
in Nanostructured lipid carriers (NLCs) for transdermal 
delivery with emulsification evaporation method. Different 
drug administration methods and dermatokinetic study 
revealed the rapid lose water of gel could enhance NLCs into 
deep skin layer. [63] 
Transferosomes 
Fernández-García R et al. prepared Transferosomes as 
nanocarriers gel have shown promising results in the 
alleviation of symptons in orthreothritis with non-severe 
skin and subcutaneous tissue disorders. [64] 
Ethosomes 
Jain S et al. formulated ethosome of Diclofenac for enhanced 
anti-inflammatory activity using 4 × 5 full-factorial design 
with Phosphatidylcholine & Cholesterol and studied skin 
permeation kinetics. [65] 
Nanotechnology based products 
Nanoparticles  
Park SY et al. formulated Sorafenib loaded Nanoparticles 
with Fat and supercritical fluid (NUFS™) to improve oral 
bioavailability and In vivo pharmacokinetics studies in 
beagle dogs demonstrated that optimized formulation of 
Sorafenib exhibited higher blood drug profiles indicating 
better absorption compared to the reference tablet 
(Nexavar®). [66] 
Yerlikaya F et al. developed and characterized Paclitaxel 
Nanoparticles with Ishikawa diagram risk assessment and 
screened by Plackett Burman design and finally 
Nanoparticles were optimized using Box Behnken design. In 
vitro cytotoxicity test showed that the developed 
Nanoparticles are more efficient than free Paclitaxel in terms 
of antitumor activity. [67] 
Nanostructured lipid carrier 
Gurumukhi VC et al. fabricated Nanostructured lipid carrier 
(NLC) encapsulating Efavirenz explored characterizations 
and in vivo safety resulting high drug encapsulated potential 
nanocarrier to enhance bioavailability and confirms safety 
with promising acceptable criteria. [68] 
Nanoliposomes 
Mahtab A et al. formulated Teriflunomide loaded 
Nanoliposomes prepared with Thin-film hydration technique 
for treatment of Rheumatoid arthritis. In vivo 
pharmacokinetic study results revealed sustained release 
profile with higher therapeutic efficacy of the drug at the 
inflammatory site compared with Teriflunomide solution. [69] 
Nanosuspension 
Verma S et al. studied process of Nanosuspension 
preparation with Multiple linear regression analysis and 
ANOVA to create design space and designed model the 
process of Microfluidization for predictive purposes. [70] 
Nanoemulsion 
Negi P et al. formulated biocompatible Lidocaine and 
Prilocaine loaded Nanoemulsion system for enhanced 
percutaneous absorption and superior permeation rates 
with higher concentrations of the drugs in skin layers from 
the optimised formulations when compared to marketed 
cream. [71] 
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Inhalation products 
Microparticles 
Zhang L et al. optimized Budesonide loaded large porous 
Microparticles for Inhalation drug delivery. [72] 
Dry powder inhalers 
Buttini F et al. studies development of Dry powder inhalers 
with QbD framework. [73] 
Nasal Products 
Bartos C et al. formulated Levodopa containing Dry powder 
for Nasal delivery.  Based on risk assessment, Levodopa and 
Chitosan or Sodium hyaluronate as mucoadhesive matrix 
formers were co-milled using planetary ball mill to prepare 
Microparticles as drug delivery systems. [74] 
Injectable Formulations 
Lipid injectable emulsion 
Deng Y et al. prepared fat soluble vitamins Lipid injectable 
emulsion & design space was obtained with DoE. Safety of 
the optimal emulsion was evaluated as acceptable through 
the determination of lysophospholipid content and an in 
vitro hemolysis assay. [75] 
Lyophilized liposomes 
Porfire A et al. developed lyophilized Liposomes with 
Simvastatin to increase shelf-life of Liposomes with Design 
space. [76] 
Self Nanoemulsified Drug Delivery System (SNEDDS) 
Zidan AS et al. studied product variability of a SNEDDS of 
Cyclosporine A & demonstrated the ability to understand the 
impact of nanodroplets size on the SNEDDS variability (Size) 
by different product analyzing tools such as Near Infrared 
(NIR) and Chemometric analysis. [77] 
Targeted Drug Delivery 
Microspheres for colon-specific delivery 
Hales D et al. formulated Enoxaparin sodium loaded 
polymeric Microspheres for colon-specific delivery then 
CPPs and CQAs were identified and achieved design space. 
[78] 
Bone targeting therapeutic Radiopharmaceutical 
Lange R et al. prepared small scale process for Rhenium 188 
HEDP which is a therapeutic Radiopharmaceutical for 
treatment of Osteoblastic bone metastases for bone 
targeting. The effect of CPPs on product quality and stability 
of 188Re-HEDP was studies. [79] 
Limicubes 
Javed MN et al. developed and optimized Bicontinuous 
cuboidal shaped Mucoadhesive Microcrystalline delivery 
systems (Limicubes) for oral delivery of Rosuvastatin. [80] 
Solid Oral products 
Bilayer combination tablet 
Ah Ram Lee et al. optimized formulation of a bilayer 
combination tablet Telmisartan and Amlodipine besylate 
(Telmiduo®) manufactured via high shear wet granulation 




Controlled Release product  
Saurí J et al. studied physicochemical phenomena involved in 
Controlled release of Captopril matrix tablets with DoE. [82] 
Pellets  
Wang J et al. developed Naproxen loaded core pellets for 
Colon specific pellets and used Plackett Burman design to 
screen potential high risk factors. [83] 
Fluid bed granulation  
Lourenço V et al. studied industrial Pharmaceutical fluid bed 
granulation with QbD.[84] 
Spray drying  
Baldinger A et al. optimized Spray drying process with DoE. 
Non-invasive NIR measurement was used for correlating the 
CQA particle size with size determined by laser diffraction. 
[85] 
Roller Compaction 
Hsu SH et al. studied modeling and control of Roller 
compaction for pharmaceutical manufacturing with DoE. [86] 
High drug load tablet  
Sun CC et al. developed high drug load tablet formulation 
based on assessment of powder manufacturability for novel 
drug AMG458. [87] 
Tablet with artificial intelligence 
Aksu B et al. applied Artificial intelligence techniques to 
control the CQAs of Ramipril tablets manufactured by wet 
granulation and design space was derived using DoE with 
Artificial neural networks (ANNs). [88] 
Bioavailability Enhancement 
Chauhan MK et al. performed bioavailability enhancement of 
Polymyxin B with novel drug delivery Niosomes as carrier 
system. Formulation showed promising results in vitro 
antifungal, rat creatinine and cytotoxicity assay. [89] 
Dissolution Enhancement 
Parmar K et al. improved dissolution properties of poorly 
water soluble herbal active ingredient Embelin by 
formulating Liquisolid systems and optimized formulation 
with DoE. [90] 
Scale up 
Coating process 
Agrawal AM et al. reviewed Scale up of pan coating process 
with DoE and PAT tool. [91] 
Orodispersible films 
Bülbül EO et al. showed improvement has been achieved for 
schizophrenic patients by the production of Quetiapine 
fumarate loaded Orodispersible films and the process of 
scale up in films has been demonstrated. [92] 
Analytical QbD  
UV spectrophotometric method 
Kualiti MP et al. developed a robust UV spectrophotometric 
method for estimation of Vilazodone and showed that 
Sampling interval and slit width were the two influential 
Critical method variables which require special attention by 
the analyst while setting up the method control strategies 
and future experimentations for continual improvement in 
method performance. [93] 
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High Performance liquid chromatography (HPLC) 
Moreira CS et al. developed and optimized stability-
indicating Chromatographic method for Verapamil 
hydrochloride and its impurities in Tablets using an 
Analytical Quality by Design (AQbD) approach. [94]  
Ultrafast liquid chromatography 
Panda SS et al. studies Ultrafast liquid chromatography for 
estimation of hallucinogenic agents in drug products, drug in 
microdialysis samples, and drugs in skin diffusate samples. 
[95]                         
Ultrahigh performance liquid chromatography  
Alexander H. Schmidt et al. developed a stability indicating 
UHPLC method for Ebastine in the API and pharmaceutical 
formulations and established model for Design Space is 
accurate. [96] 
Liquid chromatography-Tandem Mass spectrometry 
method  
Pasquini B et al. developed a Liquid chromatography-
Tandem Mass spectrometry method for the determination of 
Nintedanib and its impurities. Critical method parameters 
(CMPs) and critical method attributes (CMAs) were studied 
with DoE. [97]  
Tristimulus Colorimetry 
Hetrick EM et al. studies on Integrating Tristimulus 
Colorimetry into pharmaceutical development for color 
selection and physical appearance with QbD. [98] 
Capillary electrophoresis 
Orlandini S et al. developed a Capillary electrophoresis 
method for the analysis of Zolmitriptan and its impurities. 
DoE study was conducted to achieve the Design space. [99]  
Extractables & Leachables Assessment 
Jenke D et al. studied Extractables & Leachables assessment 
& establishing a design space for terminally sterilized 
aqueous drug products stored in a plastic packaging system. 
[100] 
API manufacture 
AM Ende D et al. studied Torcetrapib manufacturing process 
with application of risk assessment, multivariate design and 
a proposed criticality assessment all of which coalesce into 
an design space. [101] 
Conclusion 
This review articulated the whole QbD process for product 
development. QbD process starts with QTPP and CQA 
identification. CMAs and CPPs are derived with risk 
assessment. Their impact on the CQAs can be studies with 
DoE tools. The information and knowledge gained from 
pharmaceutical development studies and manufacturing 
experience provide scientific understanding to support the 
design space and control strategy. Product process will be 
follow life cycle management approach with continuous 
improvement. PAT tools are utilized for the online 
monitoring of the processes. Unique applications of QbD in 
the various areas of the product development such as 
Biotechnology, Nanotechnology products, Nasal products, 
Inhalation, Injectable products, Targeted drug delivery, 
complex Solid oral, Transdermal and topical products, 
Bioavailability and dissolution enhancement, Analytical 
processes and API manufacturing etc. are described for easy 
industrial adoption. PAT tools are becoming increasingly 
famous for the online testing applications of the product thus 
current trend applications are described. Outcome of QbD 
product development will be a robust product development 
and product submission will lead to the less regulatory post 
approval queries on the changes during product life cycle 
management and continuous improvement of the process. 
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